The United Kingdom and the United States have concluded a major commercial pact that will maintain no import taxes on British drug exports being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to raise funding on pharmaceuticals through the National Health Service (NHS). This pledge ensures that tariffs on these crucial products will stay at nothing for a period of the next three years.
This deal follows earlier statements to hike duties on patented drug imports, with potential rates discussed reaching double the cost.
"This agreement between the United Kingdom strengthens the international landscape for innovative medicines and brings much-needed balance to American-British drug exports," an announcement said.
Economic Significance
Pharmaceuticals constitute one of the the United Kingdom's biggest exports to the US, which is easily the biggest market for leading companies like GSK and AstraZeneca.
Statistics reveal that in the year leading up to September, the UK sold drugs totaling £11.1bn to the US. This value made up nearly one-fifth of all goods exports in that span.
"This guarantee safeguards work, boosts funding and sets the stage for the UK to establish itself as a international leader for medical research," a government official stated.
Key NHS Changes
The pact entails several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to increase total public funding on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be limited at 15%. Last year, rebates topped 20%.
Recent Tensions
The deal follows a long-running tension between the drug companies and the British authorities over medicine costs and approval rates.
The disagreement were heightened by arguments that US consumers were paying several times more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been paused or abandoned, while major investments have been announced toward projects in the United States.
One official publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had shrunk as a share of its total funding over the last ten years.
